- A patient receiving a stable infusion of cisatracurium for neuromuscular blockade develops acute respiratory acidosis. How is this change in acid-base status expected to influence the effect of cisatracurium?
Answer: It will potentiate the neuromuscular blockade.
Respiratory acidosis (and metabolic acidosis) is known to potentiate the effects of nondepolarizing neuromuscular blockers. The exact mechanism is complex but may involve decreased plasma protein binding, altered ionization of the drug, and direct effects on the neuromuscular junction. This potentiation means that a lower infusion rate would be required to maintain the same level of blockade.
- A patient is administered a neuromuscular blocker to facilitate endotracheal intubation. Immediately following administration, transient, uncoordinated muscle contractions are observed over the chest and abdomen. These contractions cease within a minute, and flaccid paralysis develops. This initial clinical sign is most consistent with an agent that:
Answer: acts as an agonist at postsynaptic nicotinic receptors.
The initial muscle contractions (fasciculations) followed by paralysis are the hallmark clinical presentation of a depolarizing neuromuscular blocker, such as succinylcholine. This occurs because succinylcholine is an agonist at the nicotinic acetylcholine receptor on the motor end plate, causing an initial depolarization and disorganized muscle contraction before the membrane becomes unresponsive to further stimuli, leading to flaccid paralysis (Phase I block).
- A 40-year-old patient with a severe crush injury to both lower extremities requires emergency surgery. The selection of a neuromuscular blocker for rapid sequence intubation must be made carefully. Which agent is generally contraindicated in this patient due to the risk of a life-threatening electrolyte abnormality?
Answer: Succinylcholine, due to risk of severe hyperkalemia.
In patients with crush injuries, extensive burns, or upper motor neuron lesions, there is an upregulation of extrajunctional nicotinic acetylcholine receptors. Administration of succinylcholine, a depolarizing agent, causes these channels to open, leading to a massive efflux of potassium from cells into the bloodstream. This can result in life-threatening hyperkalemia and cardiac arrest.
- During surgery, neuromuscular function is monitored with a peripheral nerve stimulator. The train-of-four (TOF) response shows four twitches, with the height of the fourth twitch being only 30% of the first (TOF ratio = 0.3). Administration of edrophonium leads to an increase in the TOF ratio to 0.8. This clinical picture is most consistent with which type of neuromuscular blocker?
Answer: A nondepolarizing blocker.
This question requires two steps. First, the presence of 'fade' (TOF ratio < 0.9) indicates either a nondepolarizing block or a Phase II depolarizing block. Second, the block is reversed by edrophonium, an acetylcholinesterase inhibitor. This combination of fade and reversibility by an anticholinesterase is the classic profile of a nondepolarizing (competitive) neuromuscular blocker.
- A patient is paralyzed with rocuronium. The anesthesiologist decides to reverse the blockade with sugammadex instead of neostigmine. What is the fundamental difference in the mechanism of reversal by sugammadex compared to neostigmine?
Answer: Sugammadex directly encapsulates rocuronium molecules in the plasma, while neostigmine indirectly increases synaptic acetylcholine.
Sugammadex has a unique mechanism of action. It is a modified gamma-cyclodextrin that directly encapsulates aminosteroid neuromuscular blockers like rocuronium in the plasma. This binding is very strong, creating a concentration gradient that pulls rocuronium away from the neuromuscular junction, leading to rapid reversal. This is fundamentally different from neostigmine, which acts indirectly by inhibiting acetylcholinesterase to increase acetylcholine levels for receptor competition.
- Which statement best contrasts the primary mechanism of action of succinylcholine with that of rocuronium at the neuromuscular junction?
Answer: Succinylcholine acts as an agonist causing initial depolarization, whereas rocuronium is a competitive antagonist preventing depolarization.
This question addresses the fundamental mechanistic difference between the two classes of neuromuscular blockers. Succinylcholine is a depolarizing blocker; it acts as an agonist at the nicotinic receptor, causing depolarization. Rocuronium is a nondepolarizing blocker; it acts as a competitive antagonist, binding to the nicotinic receptor and preventing acetylcholine from binding and causing depolarization.
- The phenomenon of 'fade,' observed as a non-sustained response to tetanic or train-of-four stimulation, is characteristic of a nondepolarizing block. This is thought to be primarily due to the blockade of which of the following targets?
Answer: Presynaptic nicotinic autoreceptors that facilitate acetylcholine mobilization.
When you encounter questions about neuromuscular blockade and "fade" phenomena, you're dealing with the complex interplay between presynaptic and postsynaptic mechanisms at the neuromuscular junction.
The "fade" observed during tetanic or train-of-four stimulation under nondepolarizing blockade occurs because these agents don't just block postsynaptic receptors—they also interfere with presynaptic feedback mechanisms. Presynaptic nicotinic autoreceptors normally detect acetylcholine release and provide positive feedback to mobilize more ACh from storage sites during high-frequency stimulation. When nondepolarizing agents like vecuronium or atracurium block these presynaptic receptors (answer D), the nerve terminal can't maintain adequate ACh release during repeated stimulation, causing the characteristic weakening or "fade" of successive muscle contractions.
Answer A is incorrect because voltage-gated sodium channels aren't the primary target of nondepolarizing agents—they mainly affect nicotinic receptors. Answer B misidentifies the target entirely; acetylcholinesterase blockade would actually increase ACh availability and isn't related to fade. Answer C confuses receptor types; muscarinic receptors aren't found at the skeletal neuromuscular junction, which uses nicotinic receptors.
Remember that fade is the hallmark that distinguishes nondepolarizing from depolarizing blockade. Depolarizing agents like succinylcholine don't cause fade because they don't significantly block presynaptic autoreceptors. When you see fade mentioned in pharmacology questions, immediately think about presynaptic nicotinic receptor involvement—it's a key concept that frequently appears on exams.
- A patient in the intensive care unit is receiving intravenous gentamicin for a gram-negative infection and is also receiving intermittent boluses of vecuronium to facilitate mechanical ventilation. The clinician should be aware of a potential drug interaction that would most likely result in:
Answer: potentiation and prolongation of the neuromuscular blockade.
When you encounter questions about drug interactions in pharmacology, focus on the mechanisms of action and how drugs might enhance or interfere with each other's effects at the cellular level.
Gentamicin belongs to the aminoglycoside class of antibiotics, which has a well-documented ability to block neuromuscular transmission. Aminoglycosides interfere with calcium influx at the presynaptic nerve terminal, reducing acetylcholine release, and they also have some postsynaptic blocking effects at the neuromuscular junction. Vecuronium is a non-depolarizing neuromuscular blocking agent that competitively blocks acetylcholine receptors at the motor endplate. When used together, gentamicin enhances vecuronium's neuromuscular blocking effects through this additive mechanism, leading to answer D - potentiation and prolongation of the neuromuscular blockade.
Answer A suggests decreased duration, which contradicts the actual pharmacologic interaction - the blockade is enhanced, not shortened. Answer B implies that vecuronium would interfere with gentamicin's antibacterial activity, but neuromuscular blockers don't affect antibiotic mechanisms against bacteria. Answer C mentions tolerance development, but this interaction is about immediate pharmacodynamic enhancement, not the gradual receptor adaptation that characterizes tolerance.
Remember this key pattern: aminoglycoside antibiotics (gentamicin, tobramycin, amikacin) can significantly enhance neuromuscular blockade from any neuromuscular blocking agent. This is a high-yield interaction that's clinically significant in ICU settings where both drug classes are commonly used together.
- A patient receives a drug that causes brief, visible muscle fasciculations followed by paralysis. A subsequent dose of neostigmine is administered while the paralysis is still profound. What is the most likely outcome?
Answer: Intensification and prolongation of the paralysis.
The initial fasciculations indicate the use of a depolarizing blocker like succinylcholine, which results in a Phase I block. Neostigmine, an acetylcholinesterase inhibitor, increases the amount of acetylcholine at the synapse. During a Phase I block, the motor end plate is already depolarized by succinylcholine. The additional acetylcholine will further contribute to this depolarization, thereby intensifying and prolonging the block rather than reversing it.
- The recovery of muscle function after administration of a nondepolarizing neuromuscular blocker follows a predictable pattern. Which muscle group is typically the first to regain function?
Answer: Muscles of respiration (diaphragm).
Paralysis from nondepolarizing blockers typically begins in small, rapidly moving muscles (eyes, fingers) and progresses to larger trunk muscles, and finally the diaphragm. The diaphragm is the most resistant to blockade and therefore the last muscle group to be paralyzed and the first to recover. Recovery occurs in reverse order of onset.
- When selecting a neuromuscular blocker for a patient with a known family history of malignant hyperthermia (MH), succinylcholine is absolutely contraindicated. This is because succinylcholine, unlike nondepolarizing blockers, can:
Answer: trigger an uncontrolled release of calcium from the sarcoplasmic reticulum in susceptible individuals.
Malignant hyperthermia is a pharmacogenetic disorder of skeletal muscle. In susceptible individuals, triggering agents like succinylcholine (and volatile anesthetics) cause a defect in the ryanodine receptor (RyR1), leading to a massive and uncontrolled release of Ca²⁺ from the sarcoplasmic reticulum. This results in the hypermetabolic state characteristic of an MH crisis (muscle rigidity, hyperthermia, acidosis, etc.).
- Which of the following structural and metabolic characteristics is unique to succinylcholine compared to aminosteroid (e.g., rocuronium) or benzylisoquinolinium (e.g., atracurium) nondepolarizing blockers?
Answer: It is composed of two acetylcholine molecules linked end-to-end and is hydrolyzed by plasma cholinesterase.
Succinylcholine's structure is essentially two molecules of acetylcholine joined together. This structure allows it to act as an agonist. Its rapid breakdown by plasma butyrylcholinesterase (pseudocholinesterase) is its key metabolic feature, responsible for its short duration of action. The other options describe features of various nondepolarizing agents.
- A patient receives a prolonged infusion of succinylcholine, and the neuromuscular block transitions from Phase I to Phase II. Which of the following findings would be most indicative of this transition?
Answer: The block is now characterized by fade on train-of-four stimulation and is partially reversed by neostigmine.
Phase II block, which occurs after prolonged exposure to succinylcholine, clinically resembles a nondepolarizing block. Its key feature is the appearance of 'fade' on train-of-four (TOF) or tetanic stimulation. Paradoxically, unlike a Phase I block which is potentiated by acetylcholinesterase inhibitors, a Phase II block can be partially antagonized by them.
- In a patient with myasthenia gravis, there is a significant reduction in the number of functional nicotinic acetylcholine receptors at the neuromuscular junction. How does this condition affect the patient's sensitivity to succinylcholine and vecuronium?
Answer: Decreased sensitivity (resistance) to succinylcholine and increased sensitivity to vecuronium.
Patients with myasthenia gravis have fewer ACh receptors. Succinylcholine (an agonist) requires these receptors to cause depolarization; with fewer targets, a larger dose is needed, indicating resistance. In contrast, vecuronium (a competitive antagonist) needs to block a smaller number of receptors to achieve paralysis. Therefore, a standard dose has an exaggerated effect, indicating increased sensitivity.
- A patient under general anesthesia has received rocuronium for muscle relaxation. At the conclusion of the surgery, the anesthesiologist administers neostigmine. What is the primary mechanism by which neostigmine reverses the effects of rocuronium?
Answer: By inhibiting acetylcholinesterase, leading to increased acetylcholine concentrations at the synapse.
Neostigmine is an acetylcholinesterase inhibitor. By inhibiting this enzyme, it prevents the breakdown of acetylcholine (ACh) in the neuromuscular junction. The resulting increase in ACh concentration allows ACh to outcompete the nondepolarizing blocker (rocuronium) for binding sites on the postsynaptic nicotinic receptors, thereby restoring neuromuscular transmission.
- Based on the monitoring data from the passage, which statement accurately describes the patient's condition?
Answer: The patient has a depolarizing block in Phase I.
When evaluating neuromuscular blockade, you need to understand how different types of blocks affect nerve stimulation patterns. The key monitoring parameters are twitch height reduction and the train-of-four (TOF) ratio, which reveal distinct patterns for depolarizing versus nondepolarizing blocks.
The monitoring data shows 80% twitch height reduction with a TOF ratio of 1.0. This pattern is pathognomonic for Phase I depolarizing block. In this phase, succinylcholine causes sustained depolarization of the motor endplate, making it unresponsive to further stimulation. Importantly, all four twitches in the train-of-four are equally diminished, maintaining a ratio of 1.0 even as overall strength decreases.
Option A is incorrect because nondepolarizing blocks characteristically produce fade, where the TOF ratio drops below 1.0 as later twitches become progressively weaker. Option B misses the mark entirely—the significant twitch height reduction clearly indicates neuromuscular junction blockade, not central nervous system effects. Option C describes Phase II block, which occurs with prolonged succinylcholine exposure and actually resembles nondepolarizing block with fade (TOF ratio < 1.0).
Remember this pattern: Phase I depolarizing block = reduced twitch height + TOF ratio of 1.0. This combination is unique to early succinylcholine effects. When you see preserved TOF ratio despite significant weakness, think depolarizing block in Phase I. Conversely, any fade (TOF < 1.0) suggests either nondepolarizing block or Phase II depolarizing block.
- Which of the following describes the effect of administering a nondepolarizing blocker (e.g., vecuronium) after a patient has already received an intubating dose of succinylcholine?
Answer: The effect of vecuronium will be diminished because receptors are occupied by succinylcholine.
Nondepolarizing blockers like vecuronium are competitive antagonists that require access to unoccupied nicotinic receptors. When succinylcholine is still present and occupying receptors as an agonist, vecuronium cannot effectively bind to exert its blocking effect. The vecuronium will only become fully effective as succinylcholine concentration decreases and receptors become available. This results in delayed onset or apparently reduced initial potency of the nondepolarizing agent.
